Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design -
Overall Survival (OS) for mCRPC patients treated with docetaxel for a... | Download Scientific Diagram
Progression-free survival of mCRPC patients treated with AAP | Download Scientific Diagram
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry | Prostate Cancer and Prostatic Diseases
Efficacy I PLUVICTO
Understanding what matters to metastatic castration‐resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey - George - 2023 - Cancer Medicine - Wiley Online Library
Overall survival and second primary malignancies in men with metastatic prostate cancer | PLOS ONE
mCRPC: PREVAIL Trial | HCP Site | XTANDI® (enzalutamide)
Association between CTC AR-V7 and overall survival in mCRPC. A total... | Download Scientific Diagram
PROpel Trial Efficacy – LYNPARZA® (olaparib) for BRCAm mCRPC
ASCO GU 2022: Overall Survival after Progression on First Novel Hormonal Therapy in Patients with Metastatic Castration-Sensitive Versus Castration-Resistant Prostate Cancer (mCSPC Versus mCRPC)
ASCO 2020: CARD: Overall Survival Analysis of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone
Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry | Targeted Oncology
First-line treatment with niraparib significantly improves PFS in HRR-mutated mCRPC - Medical Conferences
IJMS | Free Full-Text | The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone
The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study - ScienceDirect
Pharmaceutics | Free Full-Text | Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using 177Lu-iPSMA and 177Lu-DOTATOC: Experience after 905 Treatment Doses
Optimal sequencing of commonly used medications for treatment of metastatic castration-resistant prostate cancer - Mayo Clinic
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis–Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting - European Urology ...
Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study | Journal of Nuclear Medicine
